Arrowstreet Capital’s Standard BioTools LAB Stock Holding History

Arrowstreet Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64M	Buy	+1,991,426	New	+$1.88M	﹤0.01%	1565
2020 Q4	–	Sell	-429,883	Closed	-$3.19M	–	2424
2020 Q3	$3.19M	Sell	429,883 -361,490	-46%	-$2.5M	0.01%	1355
2020 Q2	$3.17M	Buy	+791,373	New	+$2.76M	0.01%	1254
2016 Q4	–	Sell	-51,901	Closed	-$416K	–	2130
2016 Q3	$416K	Buy	+51,901	New	+$477K	﹤0.01%	1292
2014 Q1	–	Sell	-18,520	Closed	-$710K	–	1238
2013 Q4	$710K	Buy	18,520 +13,384	+261%	+$394K	﹤0.01%	904
2013 Q3	$113K	Buy	+5,136	New	+$101K	﹤0.01%	956

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Arrowstreet Capital's LAB Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Standard BioTools (LAB) in Q2 2026: 1,991,426 shares worth $1.64M. The stake represents ﹤0.01% of the portfolio and ranks #1565 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in LAB as recently as Q3 2020.

Arrowstreet Capital first reported a position in LAB in Q3 2013 and has held it in 6 quarters since. The position peaked at $3.19M in Q3 2020. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Arrowstreet Capital held 1,991,426 shares of Standard BioTools worth $1.64M as of Q2 2026.
Standard BioTools was a new Arrowstreet Capital position in Q2 2026.
Standard BioTools made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1565 holding.
Arrowstreet Capital first reported a position in Standard BioTools in Q3 2013 and has held it in 6 quarters since.
Arrowstreet Capital's Standard BioTools position peaked at $3.19M in Q3 2020.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.